ClinicalTrials.Veeva

Menu

Continuous and Non-invasive Measurements by Task Force® CORE/CARDIO in Autonomic Function Testing (AFT)

C

CNSystems Medizintechnik

Status

Begins enrollment in 2 months

Conditions

Orthostatic Intolerance
Autonomic Dysfunction

Treatments

Diagnostic Test: Autonomic Function Testing

Study type

Observational

Funder types

Industry

Identifiers

NCT05977335
AFTs Task Force® CORE/CARD

Details and patient eligibility

About

Background: The investigational device, "Task Force® CORE" (TFC, CNSystems Medizintechnik GmbH, Graz, Austria) together with the "Task Force® CARDIO" (TFCARDIO, CNSystems Medizintechnik GmbH, Graz, Austria) medical device software, is a new CE-marked medical device for continuous non-invasive determination of blood pressure (BP), cardiac output (CO) and derived parameters based on the well established CNAP® (continuous non-invasive arterial pressure) technology by CNSystems.

Aim: The primary aim of this prospective, method comparison, open study is data acquisition for the performance evaluation of the TFC during autonomic function testing in comparison with an clinically accepted reference method. Setting: The setting of the clinical investigation will be the autonomic function testing laboratory at the Department of Neurology, the University Hospital Center Zagreb.

Inclusion criteria: Patients who are over 18 years and who provide written informed consent.

Sample size: The study has an calculated sample size of 70 patients. Considering a drop-out rate of 5%, a total of 75 patients will be included.

Statistics: Descriptive statistics, values for the percentage error and correlation estimates will be derived. Furthermore, scatterplot, Bland-Altman analysis, concordance analysis of parameter changes and further comparative statistics will be performed.

Enrollment

75 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients (patients aged ≥ 18 years)
  • Patients giving written informed consent to participate in the study.
  • Patients with intact perfusion of both hands evidenced by a positive Allen's test.
  • Patients with orthostatic intolerance will be included

Exclusion criteria

  • Patients with vascular implants at the sites of non-invasive BP measurement (fingers or upper arms)
  • Very low perfusion in the periphery
  • Arterial vascular diseases (arteriosclerosis, Raynaud's syndrome, endarteritis obliterans, collagenosis, severely advanced vascular diseases (PAOD))
  • Patients with significant edema in the fingers
  • Patients with atrial fibrillation
  • Patients with valvular disease of grade 2 or above
  • Patients with ventricular assist devices
  • Subjects not passing the Allen's test for both hands.
  • Patients with a large lateral difference in BP (> 15 mmHg for systolic BP and/or >10 mmHg for diastolic BP) or with same arm measurement differences > 10 mmHg in systolic or diastolic BP during assessment of lateral differences

Trial design

75 participants in 1 patient group

Orthostatic Intolerance Patients
Treatment:
Diagnostic Test: Autonomic Function Testing

Trial contacts and locations

0

Loading...

Central trial contact

Chief Technology Officer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems